Amitriptyline

Introduction Overview

Generic Name

amitriptyline

Brand Name

Elavil

Dosage Form

oral tablet

Drug Class

Tricyclic antidepressants

Pharmacokinetics

Absorption:
Amitriptyline is well absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically occurring within 4 to 8 hours. The drug undergoes extensive first-pass metabolism in the liver, which significantly reduces its bioavailability, estimated to be approximately 30% to 60%. The rate and extent of absorption may be influenced by food intake, gastrointestinal pH, and motility. Amitriptyline’s lipophilic nature facilitates its absorption.

Distribution:
Once absorbed, amitriptyline is widely distributed throughout the body, with a large volume of distribution (approximately 10 to 20 L/kg), indicating extensive tissue uptake. It crosses the blood-brain barrier efficiently due to its high lipophilicity, which underlies its central nervous system effects. It also crosses the placental barrier and is found in breast milk. Approximately 93% of amitriptyline binds to plasma proteins, mainly albumin, which influences its free pharmacologically active concentration.

Metabolism:
Amitriptyline undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2D6 and CYP1A2. The major metabolic pathways include demethylation to nortriptyline (an active metabolite with pharmacological activity comparable to amitriptyline), hydroxylation, and conjugation. Nortriptyline is further metabolized into inactive metabolites. Genetic polymorphisms affecting CYP2D6 can significantly alter the metabolism and plasma concentrations of amitriptyline and nortriptyline, impacting efficacy and risk of adverse effects.

Elimination:
Elimination of amitriptyline and its metabolites is primarily renal. The elimination half-life of amitriptyline ranges from 10 to 28 hours, with considerable interindividual variability. It takes approximately 5 half-lives (2 to 6 days) for amitriptyline to be mostly cleared from the body. Impaired hepatic or renal function can prolong elimination and increase drug plasma levels, necessitating dosage adjustments. Amitriptyline is excreted in urine both as metabolites and unchanged drug to a limited extent.

Dosage Forms

Available Dosage Forms:
Amitriptyline is commonly formulated as oral tablets. The brand Elavil, although discontinued in the US, was typically available as tablets with strengths including 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. Generic amitriptyline formulations are similarly available in these strengths.

Dosages for Adults and Adolescents:
For adults with depression, the usual initial dose is 75 mg per day orally, divided into multiple doses. This dose can be increased to a maximum of 150 mg per day as needed. Alternatively, some outpatient regimens begin with 50 to 100 mg given as a single dose at bedtime, titrating up to 150 mg/day. In inpatient settings, initial doses may begin at 100 mg daily with maintenance doses between 40 to 100 mg once daily at bedtime, with a maximum dose of 300 mg/day. Dose escalation should be gradual, ideally given late in the afternoon or at bedtime due to sedative effects.
For adolescents aged 12 years or older, similar dosing applies with initial doses of 10 mg three times daily plus 20 mg at bedtime, titrating based on response.

Specific Patient Populations:
Elderly patients often require reduced initial doses (e.g., 10 mg three times daily and 20 mg at bedtime) due to increased sensitivity and altered pharmacokinetics with aging. Careful monitoring of plasma drug levels and clinical responses is advised. Patients with hepatic or renal impairment may also require dosage adjustments due to decreased metabolism and elimination capacity. Amitriptyline is not approved for use in children under 12 years old.

Clinical guidelines emphasize continued maintenance therapy for at least 3 months after symptom remission to reduce relapse risk. Dose adjustments should always be guided by clinical efficacy and tolerability.

Mechanism Of Action

Amitriptyline is a tricyclic antidepressant that exerts its pharmacological effects primarily by inhibiting the reuptake of neurotransmitters serotonin (5-HT) and norepinephrine (NE) into presynaptic nerve terminals, thereby enhancing their synaptic availability in the central nervous system. This increase in neurotransmitter levels is thought to modulate mood and relieve depressive symptoms.

At the molecular level, amitriptyline binds with high affinity to the serotonin transporter (SERT) and the norepinephrine transporter (NET), blocking their function. This inhibition prevents neurotransmitter reabsorption, resulting in prolonged stimulation of postsynaptic receptors. Over time, this leads to adaptive changes in receptor sensitivity and neuronal circuitry associated with mood regulation.

Additionally, amitriptyline exhibits affinity for various receptor types, including antagonism of histamine H1 receptors, muscarinic cholinergic receptors, and alpha-1 adrenergic receptors. The H1 receptor blockade contributes to its sedative side effects, while muscarinic antagonism explains anticholinergic side effects such as dry mouth and constipation. Alpha-1 receptor blockade can lead to orthostatic hypotension.

Clinical studies suggest that the balance of serotonin and norepinephrine modulation by amitriptyline provides robust antidepressant efficacy, often more potent in certain patients than selective serotonin reuptake inhibitors (SSRIs). Its active metabolite nortriptyline shares similar mechanisms. The broad receptor profile also accounts for the drug’s diverse therapeutic and adverse effects.

Pharmacological Actions

Inhibition of serotonin and norepinephrine reuptake in the central nervous system, enhancing neurotransmitter availability
Sedative effects resulting from histamine H1 receptor antagonism
Anticholinergic activity via muscarinic receptor blockade leading to decreased parasympathetic activity
Alpha-1 adrenergic receptor antagonism causing vasodilation and potential orthostatic hypotension
Modulation of central monoaminergic pathways implicated in mood and anxiety disorders
Active metabolite nortriptyline contributes to sustained antidepressant effect
Reduction of neuropathic pain through central modulation of nociceptive pathways
Alters sleep architecture, increasing slow-wave sleep and reducing rapid eye movement (REM) sleep
Exerts antiemetic effects possibly related to antagonism of central adrenergic receptors
May reduce symptoms of migraine prophylaxis and chronic pain syndromes through CNS effects
Influences cardiac conduction by blocking sodium channels at high doses, contributing to cardiotoxicity in overdose scenarios

Therapeutic Or Clinical Uses

Treatment of major depressive disorder including melancholic and endogenous depression
Management of neuropathic pain such as diabetic neuropathy and postherpetic neuralgia
Adjunctive treatment in anxiety disorders and panic attacks
Prevention of migraine headaches in selected patients
Alleviation of chronic tension-type headaches
Treatment of insomnia associated with depression due to sedative effects
Management of irritable bowel syndrome symptoms via modulation of visceral pain
Pharmacologic option for chronic pain syndromes including fibromyalgia
Off-label use in treatment of post-traumatic stress disorder (PTSD)
Symptomatic treatment in adjunct to therapy for enuresis (bedwetting) in older children and adolescents
Relief of depressive symptoms secondary to bipolar disorder during depressive phases (with caution)

Side Or Adverse Effects

Sedation and drowsiness, especially during initial treatment period
Anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention
Weight gain and increased appetite related to histamine H1 receptor blockade
Orthostatic hypotension due to alpha-1 adrenergic blockade, risk of dizziness and falls
Cardiac conduction abnormalities including QT prolongation and arrhythmias at high doses
Sexual dysfunction including decreased libido, erectile dysfunction, and delayed orgasm
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or constipation
Confusion, cognitive impairment, or delirium, particularly in elderly patients
Increased risk of seizures especially in patients with seizure disorders or overdose
Photosensitivity reactions leading to increased risk of sunburn
Potential liver enzyme elevation and rare cases of hepatotoxicity
Rare allergic reactions including rash, urticaria, and angioedema
Mood alterations including agitation, anxiety, and risk of suicidal ideation especially in young adults
Withdrawal symptoms if the drug is discontinued abruptly: headache, nausea, irritability, sleep disturbances
Urinary retention or difficulty urinating, particularly in patients with prostate hypertrophy

Precautions

Avoid use in patients with recent myocardial infarction due to risk of cardiac complications
Use cautiously in individuals with a history of bipolar disorder or schizophrenia
Monitor patients for emergence of suicidal thoughts particularly during initial treatment weeks
Adjust dose or avoid in patients with liver or renal impairment due to altered metabolism and clearance
Screen for history of seizures, as amitriptyline may lower seizure threshold
Use with caution in elderly patients due to increased sensitivity to side effects and risk of falls
Avoid concomitant use with monoamine oxidase inhibitors and allow adequate washout periods
Monitor blood glucose closely in diabetic patients as amitriptyline may alter glycemic control
Assess cardiac function before initiation in patients with known heart disease
Caution in patients with glaucoma or urinary retention due to anticholinergic activity
Gradually taper dose upon discontinuation to minimize withdrawal symptoms
Avoid alcohol consumption to prevent enhanced CNS depression and risk of toxicity
Inform patients about photosensitivity risk and advise sun protection measures
Use during pregnancy only if benefits outweigh risks, as safety data are limited
Exercise caution when driving or operating heavy machinery until drug effects are known

Warnings

Contraindicated in patients who have recently had a heart attack due to risk of fatal arrhythmias
Do not use concurrently or within 14 days of monoamine oxidase inhibitors to avoid hypertensive crisis
Increased risk of suicidal ideation and behaviors in patients younger than 24 years when initiating therapy
Drug overdose with amitriptyline can be fatal; emergency medical intervention is required
May cause QT interval prolongation and serious cardiac arrhythmias, particularly in overdose
Abrupt cessation may result in withdrawal symptoms including irritability and sleep disturbance
Co-administration with other CNS depressants can potentiate sedation and respiratory depression
Use cautiously in patients with a history of bipolar disorder to avoid inducing manic episodes
Potential for serotonin syndrome if combined with other serotonergic agents
Risk of orthostatic hypotension and falls especially in elderly or debilitated patients
Avoid use in children under 12 years as safety and efficacy are not established
Patients should be closely monitored for signs of worsening depression or unusual behavior changes
May impair heat regulation; caution in hot weather or during activities leading to overheating
Use in pregnancy should be carefully considered; breastfeeding mothers should consult healthcare providers
Possibility of rare but severe allergic reactions necessitating immediate medical attention

Contraindication

Recent myocardial infarction or unstable heart disease
Concomitant use or use within 14 days of monoamine oxidase inhibitors (MAOIs)
Known hypersensitivity to amitriptyline or any component of the formulation
Severe hepatic impairment without close medical monitoring
Patients with untreated narrow-angle glaucoma
Concurrent use of cisapride or other drugs known to prolong QT interval significantly
Use in children under 12 years due to insufficient safety data
Patients with acute recovery phase following stroke or severe cardiovascular disorders
Avoid use in individuals with history of hypersensitivity to other tricyclic antidepressants
Use of amitriptyline with linezolid or methylene blue (MAOI-like drugs) is contraindicated

Drug Interactions

Concomitant use with monoamine oxidase inhibitors can cause hypertensive crises or serotonin syndrome
Additive CNS depressant effects when used with alcohol, benzodiazepines, opioids, or other sedatives
Potential for increased anticholinergic side effects with antihistamines or antipsychotics
Co-administration with SSRIs or SNRIs increases risk of serotonin syndrome
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase plasma levels of amitriptyline, raising toxicity risk
Inducers of CYP450 enzymes (e.g., carbamazepine, phenytoin) may reduce therapeutic efficacy
Interaction with drugs prolonging QT interval increases risk of cardiac arrhythmias
Concomitant use with clozapine or other tricyclic antidepressants increases anticholinergic burden
Combination with monoamine oxidase inhibitors, linezolid, or methylene blue is contraindicated
Use with drugs that lower seizure threshold may increase risk of seizures
Beta-blockers and other antihypertensives may have enhanced hypotensive effects
Warfarin metabolism may be altered, necessitating monitoring of INR
Interactions with cold or allergy medications (e.g., diphenhydramine) may increase sedation and anticholinergic effects
Bronchodilators used for asthma may interact and cause cardiovascular side effects
Overactive bladder medications and other anticholinergics can potentiate amitriptyline side effects

Preparations Of The Drug

Oral tablets available in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg
Generic amitriptyline formulations identical in strength and administration
Extended-release formulations generally not available; standard tablets used
Packaging includes blister packs and bottles with child-resistant caps
No parenteral formulations commonly used; amitriptyline is primarily administered orally
Storage at room temperature away from moisture and heat to maintain stability
Packaging contains patient information leaflets detailing dosing and side effects
Combined formulations with other drugs are not typical for amitriptyline
Available as generic brand equivalents following discontinuation of Elavil brand name
No topical or intravenous preparations currently approved for clinical use